domagrozumab domagrozumab domagrozumab (pf-06252616) (inn) is a humanized monoclonal antibody designed for the treatment of duchenne muscular dystrophy. domagrozumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetgdf-8clinical dataother namespf-06252616atc codenoneidentifierscas number1629605-31-7chemspidernoneunii516md5wq24keggd11047chemical and physical dataformulac6366h9826n1690o2008s46molar mass143639.22 g·mol−1 this drug was developed by pfizer.